CC BY-NC-ND 4.0 · Endosc Int Open 2021; 09(08): E1186-E1187
DOI: 10.1055/a-1393-5780
Editorial

Follow-up after EUS-guided radiofrequency ablation for pancreatic lesions: With more answers, come more questions

Ryan Law
Mayo Clinic, Department of Gastroenterology and Hepatology, Rochester, Minnesota, United States
,
Michael J. Levy
Mayo Clinic, Department of Gastroenterology and Hepatology, Rochester, Minnesota, United States
› Author Affiliations

Radiofrequency ablation (RFA) is a recently described technology for the treatment of low-grade pancreas lesions, such as neuroendocrine tumors (NETs) and pancreatic cystic neoplasms (PCNs). Early data suggest that this intervention is safe and effective; however, numerous questions remain regarding its role in our therapeutic armamentarium. RFA employs electromagnetic energy and high-frequency alternating currents to induce coagulative necrosis and fibrotic changes in highly thermosensitive tissues, such as the pancreas [1] [2] [3] This method of cell death causes the release of intracellular antigens known to stimulate a delayed immune response as well [4]. To date, a paucity of studies have examined the utility of RFA in treating pancreas lesions, and data on long-term outcomes are non-existent.



Publication History

Publication Date:
16 July 2021 (online)

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany